Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Glioblastoma 1Fallopian Tube Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Colorectal Cancer Metastatic 1Central Nervous System Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Merkel Cell 1Brain Neoplasms 1Astrocytoma 1

Interventions

Carboplatin 23Paclitaxel 14pembrolizumab 8liposomal doxorubicin 7Bevacizumab 5Specimen Handling 4olaparib 3niraparib 3epacadostat 3Topotecan 3Taxes 3Nivolumab 3Magnetic Resonance Spectroscopy 3Gemcitabine 3Cyclophosphamide 3Biopsy 3sarilumab 2rucaparib 2poly ICLC 2durvalumab 2cemiplimab 2STA 9090 2Injections 2Immunoglobulin G 2Drug Therapy 2Docetaxel 2Disulfides 2Cisplatin 2veliparib 1tremelimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Fallopian Tube Neoplasms × aflibercept × Clear all
NCT00436501 2019-02-26

VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
58 enrolled 16 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡